Facebook RSS Twitter
Thu, Oct 9, 2025
Facebook RSS Twitter
Home CA Medical Page 5

CA Medical

California Medical News – including research, biotech, medical services and related

Epeius Biotechnologies’ Tumor-Targeted Rexin-G Receives FDA Orphan Drug Designation for Osteosarcoma Treatment

Cindy Holden -

Fertility Specialist, Steven A. Brody, M.D., Ph.D. to Anchor New San Diego Medical Institute

Cindy Holden -

IV Infusions of Rexin-G Demonstrates Dose-Dependent Anti-Tumor Activity Without Toxicity

Cindy Holden -

Rexin-G Followed by Reximmune-C Induce Tumor Necrosis and Recruitment of Tumor Infiltrating Lymphocytes

Cindy Holden -

Rexin-G Monotherapy Reveals Significant Biological Activity without Toxicity in Chemo-Resistant Metastatic Breast Cancer (ASCO 2008)

Cindy Holden -

M2SYS Fingerprint Software Selected by Innovative Marijuana Caregiver Logistics

Cindy Holden -

ASCO 2008: Tumor-Targeted Rexin-G Demonstrates Dose-Dependent Anti-Tumor Activity without Toxicity in Metastatic Pancreatic Cancer

Cindy Holden -

Northern California Physician Incorporates His Personal Experience Into an Individualized Treatment Approach for Optimizing Fertility

Cindy Holden -

Interim Analysis of Phase I/II Study of Rexin-G Confirms Efficacy

Cindy Holden -

Cypress Systems, Inc. Launches Cancer Prevention Health Campaign

Cindy Holden -

Mark Whitacre, Ph.D. Promoted to COO at Cypress Systems, Inc. and a Warner Bros. Movie to be Filmed About Him

Cindy Holden -

Epeius Bio Awarded U.S. Patent for Targeted Injectable Gene Delivery In Vivo

Cindy Holden -

MedSort Online Health Record System Ensures Patient Privacy and Physician Efficiency

Cindy Holden -

As Targeted Gene Therapy Comes of Age in Clinical Medicine, Epeius Biotechnologies Applauds Their Academic Contemporaries

Valerie Gotten -

ASEAN News: Epeius Biotechnologies Gains Commercial Approval for Rexin-G(R), a Tumor-Targeted Gene-Based Medicine for Metastatic Cancer

Cindy Holden -

FDA Approves the Opening of a Phase II Registration Protocol Using REXIN-G for Osteosarcoma

Cindy Holden -

San Diego Office Added by Always Best Care Senior Services

Cindy Holden -

Epeius Biotechnologies Leads with Keynote Address on the Advent of Pathotropic Medicine for Cancer at the Global Pharma R&D Summit Conference...

Cindy Holden -

Sunshine Media, Inc. Announces M.D. News Magazine to the Inland Empire Marketplace

Cindy Holden -

New Treatments for Kidney Cancer Offer Hope, but Create Difficult Choices for Cancer Patients

Valerie Gotten -

Renowned Fertility and Hormonal Health Expert Dr. Robert Greene to Lead Sacramento Reproductive Practice

Cindy Holden -

California Biotech Company Takes Aim at Pancreatic Cancer With an Advanced Phase I/II Clinical Trial

Cindy Holden -

Osmetech Licenses Roche Hot Start® Polymerase Technology

Valerie Gotten -

Epeius Biotechnologies Draws the Sword of Targeted Gene Delivery (Rexin-G) from the Stone of Chemistry and Physics

Valerie Gotten -

Epeius Biotechnologies Gains FDA Approval for Two New Clinical Trials Using Rexin-G(TM) for Breast Cancer and Sarcoma

Valerie Gotten -

Epeius Biotechnologies to Present the Advent of Tumor Targeting Technology at C21 BioVentures Conference

Cindy Holden -

Tehachapi Hospital Foundation Seeks Funds to Save Rural Critical Access Facility

Valerie Gotten -

DermHair Clinic Provides New Hope and Applies New Technique for Baldness

Valerie Gotten -

Japanese Study Confirms Safety and Efficacy of Intravenous Rexin-G

Cindy Holden -

Rexin-G, The World’s First Tumor-Targeted Gene Therapy Vector, Stymies Metastatic Cancer

Valerie Gotten -
1...345Page 5 of 5

FEATURED NEWS

© 2000-2025 Neotrope®